Company Intelligence

Rosebud Biosciences

Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery…

Official Website
In this profile

Quick Facts

  • Founded 2022
  • Headquarters San Francisco, United States
  • Country United States
  • Industry AI in Healthcare
  • Company Type Early
  • Status Active
  • Website Official site
  • Last Reviewed Aug 2026

Executive Summary

Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models.

Why It Matters

Growing micro-organs to find new drugs

Recent Developments

  1. 2022 Company founded

    Rosebud Biosciences was founded in 2022 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

AI in Healthcare Open industry

Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Request a correction if you represent this company or believe information is inaccurate.

Explore Related Intelligence

Products Product directory Founders Founder profiles Reports Open reports Industries Explore sectors

The AI Brief

Weekly company intelligence in your inbox.

Subscribe